A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
Running, not enrolling · Phase 1
Conditions studied: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
In brief
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Key facts
- Study ID
- NCT05163028
- Run by
- HUYABIO International, LLC.
- People needed
- 42
- Starts
- 2021-12-13
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2025-09-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- California Cancer Associates for Research and Excellence, Inc. (cCare) — Encinitas, California, United States
- Providence Medical Foundation — Fullerton, California, United States
- California Cancer Associates for Research and Excellence, Inc. (cCare) — San Marcos, California, United States
- Sarcoma Oncology — Santa Monica, California, United States
- UCLA Hematology/Oncology — Santa Monica, California, United States
- Orlando Health, Inc. — Orlando, Florida, United States
- BRCR Medical Center — Plantation, Florida, United States
- Gabrail Cancer Center — Canton, Ohio, United States
- Texas Oncology - Tyler — Tyler, Texas, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
- Pan American Center for Oncology Trials (PanOncology Trials) — Rio Piedras, Puerto Rico, Puerto Rico
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.